PBAC's latest decision on Glycopyrronium bromide: Noted (2015). Considered for COPD patients in combination with LAB/ICS (long-acting beta-2 agonist/inhaled corticosteroid), specifically salmeterol/fluticasone.
PBAC outcome
Noted
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2013
Submissions
2
2013 → 2015
Eligible population
Patients with COPD receiving combination therapy with salmeterol/fluticasone.
Therapy area
Respiratory
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Lung function and health status
Key trials
GLISTEN
Comparator
tiotropium
Economic model
Not modelled
ICER note
No economic evaluation provided; this was a data submission to confirm comparative effectiveness and safety of an already-restricted listing.
Submission history
Nov 2013: Recommended with restriction · Restricted